Loading clinical trials...
Loading clinical trials...
An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A
Conditions
Interventions
Moroctocog alfa (AF-CC)
Moroctocog alfa (AF-CC)
Locations
28
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
OHSU Investigational Pharmacy
Portland, Oregon, United States
Oregon Health & Science University
Portland, Oregon, United States
Childrens Medical Center Dallas
Dallas, Texas, United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Start Date
December 1, 2007
Primary Completion Date
April 1, 2018
Completion Date
April 1, 2018
Last Updated
January 11, 2019
NCT07226206
NCT05987449
NCT04645199
NCT06703606
NCT06702579
NCT03818763
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions